New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
07:22 EDTBINDBIND Therapeutics barasertib data positive, says JMP Securities
JMP Securities notes that pre-clinical studies of BIND's barasertib showed enhanced anti-tumor activity and reduced bone marrow toxicity. The firm thinks the company could overcome the need for lengthy drug infusion and high rates of febrile neutropenia, shown in a previous studiy, by extending the half-life of the drug. The firm reiterates a $30 price target and Outperform rating on the stock.
News For BIND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
09:14 EDTBINDOn The Fly: Pre-market Movers
Subscribe for More Information
07:31 EDTBINDBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
June 22, 2015
10:16 EDTBINDBIND Therapeutics names Andrew Hirsch as president and CEO
BIND Therapeutics announced that Andrew Hirsch has been appointed president and CEO of the company. Hirsch had been serving in the role on an acting basis since March. Hirsch has also been elected to BIND’s Board of Directors. “After a thorough evaluation of internal and external candidates, the Board is confident that Andrew is the right person to lead the next phase of the company’s growth,” said Daniel Lynch, Chairman, BIND Therapeutics Board of Directors.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use